TY - JOUR
T1 - Clinical Impact and Mechanisms of Nonatherosclerotic Vascular Aging
T2 - The New Kid to Be Blocked
AU - Jouabadi, Soroush Mohammadi
AU - Ataabadi, Ehsan Ataei
AU - Golshiri, Keivan
AU - Bos, Daniel
AU - Stricker, Bruno H.C.
AU - Danser, A. H.Jan
AU - Mattace-Raso, Francesco
AU - Roks, Anton J.M.
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/12
Y1 - 2023/12
N2 - Ischemic cardiovascular disease and stroke remain the leading cause of global morbidity and mortality. During aging, protective mechanisms in the body gradually deteriorate, resulting in functional, structural, and morphologic changes that affect the vascular system. Because atherosclerotic plaques are not always present along with these alterations, we refer to this kind of vascular aging as nonatherosclerotic vascular aging (NAVA). To maintain proper vascular function during NAVA, it is important to preserve intracellular signalling, prevent inflammation, and block the development of senescent cells. Pharmacologic interventions targeting these components are potential therapeutic approaches for NAVA, with a particular emphasis on inflammation and senescence. This review provides an overview of the pathophysiology of vascular aging and explores potential pharmacotherapies that can improve the function of aged vasculature, focusing on NAVA.
AB - Ischemic cardiovascular disease and stroke remain the leading cause of global morbidity and mortality. During aging, protective mechanisms in the body gradually deteriorate, resulting in functional, structural, and morphologic changes that affect the vascular system. Because atherosclerotic plaques are not always present along with these alterations, we refer to this kind of vascular aging as nonatherosclerotic vascular aging (NAVA). To maintain proper vascular function during NAVA, it is important to preserve intracellular signalling, prevent inflammation, and block the development of senescent cells. Pharmacologic interventions targeting these components are potential therapeutic approaches for NAVA, with a particular emphasis on inflammation and senescence. This review provides an overview of the pathophysiology of vascular aging and explores potential pharmacotherapies that can improve the function of aged vasculature, focusing on NAVA.
UR - http://www.scopus.com/inward/record.url?scp=85175449806&partnerID=8YFLogxK
U2 - 10.1016/j.cjca.2023.07.022
DO - 10.1016/j.cjca.2023.07.022
M3 - Review article
C2 - 37495207
AN - SCOPUS:85175449806
SN - 0828-282X
VL - 39
SP - 1839
EP - 1858
JO - Canadian Journal of Cardiology
JF - Canadian Journal of Cardiology
IS - 12
ER -
